Table 3.
Prioritised research projects for 2018, 2019 and 2020
| Project | Investigator |
|---|---|
| 2018 | |
| Biologics in severe asthma: utilisation patterns, causes for discontinuation and switching and adverse outcomes | Professor Andrew Menzies-Gow (UK) |
| Hidden severe asthma patients in primary care vs. ISAR | Professor David Price (Singapore) |
| Relationship between socioeconomic status and asthma outcomes | Professor Liam Heaney (UK) |
| The impact of exacerbation burden on lung function trajectory in a broad asthma population and severe asthma population | Professor Liam Heaney (UK) |
| Biomarker Relatability in the International Severe Asthma Registry (BRISAR) | Dr. Eve Denton and Dr. Mark Hew (Australia) |
| Identification of predictors (i.e. biomarkers) of response to biologics | Dr. Eve Denton and Dr. Mark Hew (Australia) |
| Hidden chronic asthma within the COPD/ACO population | Professor Chin Kook Rhee (South Korea) |
| Age of onset of asthma in severe asthma patients | Dr. Enrico Heffler (Italy) |
| 2019 | |
| Describe the OCS landscape: annual consumption, prevalence, outcomes and side effects of long-term OCS users | |
| Criteria for choosing and switching between similar biological treatment options in patients with atopic and non-atopic severe eosinophilic asthma | |
| 2020 | |
| What is the impact of co-morbidity in severe asthma? | |
| Define responders and non-responders to biologics and describe their characteristics overall and per biologic | |
| Describe the clinical outcome before and after biologic treatment by biologic class, by individual biologic, and by subgroups of baseline characteristics | |
ACO asthma-chronic obstructive pulmonary disease overlap, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 second, ISAR International Severe Asthma Registry, OCS oral corticosteroids, UK United Kingdom